Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 34507.82% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 34507.82% increase, with the full-year FY2025 number at $3.7 million, changed N/A from a year prior.
  • Other Non-Current Liabilities was $1.2 million for Q4 2025 at Neuphoria Therapeutics, down from $8.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $8.1 million in Q3 2025 to a low of $3389.0 in Q4 2024.
  • A 4-year average of $1.7 million and a median of $253377.5 in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 99.81% in 2023, then surged 235344.22% in 2025.
  • Neuphoria Therapeutics' Other Non-Current Liabilities stood at $7492.2 in 2022, then soared by 99.81% to $14969.9 in 2023, then plummeted by 77.36% to $3389.0 in 2024, then surged by 34507.82% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Other Non-Current Liabilities are $1.2 million (Q4 2025), $8.1 million (Q3 2025), and $3.7 million (Q2 2025).